Grants-in-aid

We advertise for applications for grants-in-aid at the start of each year (for funding to start in January the following year).

Grants-in-aid support research for 1 to 3 years. They're awarded based on each project's:

  • relevance to cancer,
  • excellence,
  • the value of the research, and
  • the researcher's capacity to successfully complete the research described in the application.

All applications go through a rigorous peer-review process. The state Cancer Councils work in partnership with the National Health and Medical Research Council, which provides us with assessments and rankings.

In 2017 Cancer Council Victoria spent $3.2 million on grants-in-aid. Current recipients are listed below.


Dr Ashwini Chand, Prof Matthias Ernst, Prof Michael Parker
La Trobe University
Repurposing drugs for the treatment of gastrointestinal cancers (2018-20)

A/Prof Phillip Darcy, Dr Paul Beavis, Prof Dale Godfrey
Peter MacCallum Cancer Centre
Investigating the potential of mucosal associated invariant T (MAIT) cells in cancer (2018-20)

Dr Daniel Gough, Prof David Watkins, Dr Kate Sutherland, A/Prof Jake Shortt
Hudson Institute of Medical Research
Identifying new treatments for platinum resistant Small Cell Lung Cancer (2018-20) 

A/Prof Daniel Gray, Prof David Huang, Prof Andrew Roberts, Prof Terence Speed
The Walter and Eliza Hall Institute of Medical Research
Deep Profiling of Chronic Lymphocytic Leukemia During Targeted Therapy (2018-20)

A/Prof Craig Harrison, Dr Paul Gregorevic, A/Prof Jose Garcia
Monash University
Towards precision medicine for cancer cachexia (2018-20)

A/Prof Christine Hawkins, Prof Andrew Scott, A/Prof Carl Walkley
La Trobe University
Pre-clinical evaluation of IAP antagonists for osteosarcoma treatment (2018-20)

A/Prof Thomas John, Prof Andrew Scott, A/Prof Hui Gan
The Olivia Newton-John Cancer Research Institute
Novel therapeutic approaches for mesothelioma (2018-20)

Prof Ricky Johnstone, A/Prof Jake Shortt
Peter MacCallum Cancer Centre
Targeting transcriptional addiction for cancer therapy (2018-20)

Dr Gemma Kelly, Dr Marco Herold, Dr Mary Ann Anderson
The Walter and Eliza Hall Institute of Medical Research
Therapeutic targeting of the BCL-2 pro-survival protein, MCL-1, in humanised haematopoietic cancer models and patient samples using a novel BH3-mimetic drug (2018-20)

Prof Christina Mitchell, Prof Catriona McLean
Monash University
Regulation of phosphoinositide 3-phosphate tumour suppressor activity (2018-20)

Dr Donia Moujalled
Monash University
Targeting pro-survival programs in Acute Lymphoblastic Leukemia (ALL) (2018-20)

Prof David Ritchie, Dr Nicholas Huntington
The University of Melbourne
Inhibiting Bcl-2 and NK cells improves stem cell transplant outcomes in Acute Myeloid Leukaemia (2018-20)

Prof Tony Tiganis, Prof Catriona McLean
Monash University
The roles of STAT-1/3 in NASH and liver cancer (2018-20)

Dr Urmi Dhagat, Dr Sophie Broughton, Prof Michael Parker, A/Prof Louise Purton
St Vincent's Institute of Medical Research
Structural linkage between ligand discrimination and receptor activation by interleukin-3 (2017-19) 

A/Prof Hui Gan, Prof Andrew Scott, Prof John Mariadason, A/Prof Elgene Lim, Prof Niall Tebbutt
La Trobe University
Anti-EGFR drug conjugates for the treatment of colorectal and breast cancer  (2017-19) 

Prof Suzanne Garland, Prof Sepehr Tabrizi, A/Prof Richard Hillman, Dr Alyssa Cornall, Dr Fengyi Jin, Dr Jennifer Roberts, Dr Isobel Poynten, Dr Monica Molano, Dr Dorothy Machalek
The University of Melbourne
Evaluating molecular biomarkers of anal cancer risk (2017-19)

Prof John Hopper, Dr Daniel Schmidt, Dr Enes Makalic, Dr Carmel Apicella, Dr Louise Keogh, Dr Helen Frazer, Dr Pierre-Antoine Dugue, Dr Ralph Highnam, Mr Kevin Nguyen, Dr Jill Evans
The University of Melbourne
Development of automated measures from mammograms that predict masking and risk and pilot implementation into a BreastScreen service  (2017-19)

Dr Peter Janes, Prof Andrew Scott, A/Prof Thomas John
Monash University
Targeted antibody therapy for malignant mesothelioma 
Lyall Watts Mesothelioma Research Grant (2017-2019)

Dr Ian Majewski, Prof David Huang, Prof Andrew Roberts
The Walter and Eliza Hall Institute of Medical Research
Identifying and overcoming resistance to BCL2 inhibitors (2017-19) 

Dr Kate Murphy, Prof John Silke, Prof Gordon Lynch, Prof Leanne Delbridge
The University of Melbourne
Using novel Fn14 inhibitory antibodies to treat cardiac cachexia in cancer (2017-19)

Dr Lan Nguyen
Monash University
Friend or foe? Deciphering the conflicting functions of YAP in breast cancer (2017-19) 

A/Prof Helena Richardson, A/Prof Patrick Humbert, Prof Josef Penninger
La Trobe University
Regulation of cell polarity and tumourigenesis by Tetraspanin 6  (2017-19)

Dr Adam Uldrich, Dr Daniel Pellicci, Dr Ilia Voskoboinik
The University of Melbourne
The functional characterisation and anti-cancer potential of a novel subset of human gamma delta T cells (2017-19) 

A/Prof Carl Walkley, A/Prof Wallace Langdon, Dr Meaghan Wall, Dr Alistair Chalk
St Vincent's Institute of Medical Research
Understanding how changes in RNA splicing contribute to myelodysplastic syndrome and chronic myelomonocytic leukaemia (2017-19) 

A/Prof Kieran Harvey, Dr Nicola Waddell, A/Prof Kaylene Simpson
Peter MacCallum Cancer Centre
Deciphering the role of the Hippo pathway in mesothelioma
Lyall Watts Mesothelioma Research Grant (Sept 2016 - Aug 2019)

Dr Nicole Haynes, Prof Ricky Johnstone, A/Prof Sherene Loi
The University of Melbourne (Peter MacCallum Cancer Centre)
Harnessing the immune system with epigenetic therapies to treat HER2+ breast cancer (2016-18)

Dr Peter Janes, Prof Dimitar Nikolov, Dr Elgene Lim
Monash University
Novel therapeutic antibodies to fight drug resistant breast cancers  (2016-18)

Prof Stephen Nutt, A/Prof Lynn Corcoran
The Walter and Eliza Hall Institute of Medical Research
Identification of new therapeutic targets in plasma cells and multiple myeloma  (2016-18)

Dr Belinda Parker, A/Prof Phil Darcy
La Trobe University
Type 1 interferon regulators as prognostic markers and predictors of therapeutic response in triple negative breast cancer (2017-19) 

Dr Gretchen Poortinga, Prof Grant McArthur, Prof Ross Hannan
Peter MacCallum Cancer Centre
Elucidating mechanisms of resistance to therapeutic inhibition of RNA polymerase 1 transcription (2016-18) 

A/Prof Louise Purton, Dr Meaghan Wall, Dr Carl Walkley
St Vincent's Institute of Medical Research
Impact of deregulated HOXA1 splicing in myelodysplastic syndromes (2016-18)

Prof Jamie Rossjohn, Prof Andrew Brooks
Monash University
Exploring the role of human Natural Killer cells in tumour immunity (2016-18)

Dr Karen Sheppard, Prof Grant McArthur
Peter MacCallum Cancer Centre
Acquired resistance to CDK4 inhibition in melanoma  (2016-18)

Prof Andreas Strasser, Dr Daniel Gray
The Walter and Eliza Hall Institute of Medical Research
The mechanisms of cell competition that suppress cancer development (2016-18)

Prof Jose Villadangos, Prof William Heath
The University of Melbourne
Characterisation and prevention of "Stunning", a cytotoxic T lymphocyte inactivating program that impairs adoptive cell therapy against cancer (2016-18)

Dr Florian Wiede
Monash University
PTPN2 and adoptive T cell immunotherapy (2016-18)